Towards this direction, the 2020 WHO classification of tumors of soft tissue and bone included a few new entities that can be diagnosed exclusively using molecular methods, such as sarcomas with neurotrophic tyrosine receptor kinase (NTRK) fusions [5] and BCL6 corepressor (BCOR) alterations [6]. This evidence concerns the gene BCOR and soft tissue neoplasm.